Octapharma Commences Phase III Studies Of IVIG
Kim Bjornstrup, deputy chairman of Octapharma Group, said: “The development of our novel 10% IVIG is part of our ongoing commitment to invest in the development of protein
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.
The growth is primarily driven by exploration of factors influencing cellular malfunction and disease development. Additionally, innovations in epigenetic studies such as biomarker discovery and scientifically useful biomarker
Stefan Verheye, department of cardiology at Middelheim Hospital, Antwerp, said: “These clinical results suggest very promising benefits for patients. We had already demonstrated that the self-expanding and disconnectable